Cargando…

Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug

BACKGROUND: COVID-19 disease caused by SARS-CoV-2 is lacking efficient medication although certain medications are used to relief its symptoms. OBJECTIVES: We tested an FDA-approved antiviral medication namely rilpivirine to find a drug against SARS-CoV-2. METHODS: The inhibition of rilpivirine agai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ameen, Fuad, Mamidala, Estari, Davella, Rakesh, Vallala, Shravan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294774/ https://www.ncbi.nlm.nih.gov/pubmed/34326009 http://dx.doi.org/10.1016/j.jiph.2021.07.012

Ejemplares similares

In silico prediction of mozenavir as a potential drug for SARS-CoV-2 infection via binding multiple drug targets
por: Mamidala, Estari, et al.
Publicado: (2022)

Phenolic compounds as promising drug candidates against COVID-19 - an integrated molecular docking and dynamics simulation study
por: Davella, Rakesh, et al.
Publicado: (2022)

In vitro anti-HIV activity of crude extracts from Tinospora cordifolia
por: Estari, Mamidala, et al.
Publicado: (2012)

HIV-1 reverse transcriptase inhibitory activity of Aerva lanata plant extracts
por: Gujjeti, Rajendra Prasad, et al.
Publicado: (2014)

On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2
por: Sauvat, Allan, et al.
Publicado: (2020)

Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition
por: Sanna, Vanna, et al.
Publicado: (2022)

Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants
por: Smith, Steven J., et al.
Publicado: (2016)

Multi-Targeted Approaches and Drug Repurposing Reveal Possible SARS-CoV-2 Inhibitors
por: Alanazi, Khalid Mashay, et al.
Publicado: (2021)

A novel library of -arylketones as potential inhibitors of α-glucosidase: Their design, synthesis, in vitro and in vivo studies
por: Luthra, Tania, et al.
Publicado: (2017)

The SARS-CoV-2 main protease as drug target
por: Ullrich, Sven, et al.
Publicado: (2020)

SARS-CoV-2: Origin, Evolution, and Targeting Inhibition
por: Ning, Shuo, et al.
Publicado: (2021)

Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology
por: Pereira, Mariana, et al.
Publicado: (2023)

Tackling SARS-CoV-2: proposed targets and repurposed drugs
por: Joshi, Siddhi, et al.
Publicado: (2020)

Drug discovery targeting SARS-CoV-2 membrane fusion
por: Yang, Kailu, et al.
Publicado: (2023)

Targeting ACLY efficiently inhibits SARS-CoV-2 replication
por: Yuen, Terrence Tsz-Tai, et al.
Publicado: (2022)

A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment
por: Pirone, Luciano, et al.
Publicado: (2020)

Antiviral drug discovery by targeting the SARS-CoV-2 polyprotein processing by inhibition of the main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2022)

A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors
por: Ren, Peng-xuan, et al.
Publicado: (2021)

Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2
por: Jena, N.R.
Publicado: (2021)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Potential therapeutic targets and promising drugs for combating SARS‐CoV‐2
por: Zhou, Hong, et al.
Publicado: (2020)

Establishment and validation of a drug-target microarray for SARS-CoV-2
por: Chen, Peng, et al.
Publicado: (2020)

Drug discovery and development targeting the life cycle of SARS-CoV-2
por: Su, Haixia, et al.
Publicado: (2021)

Potential drug targets of SARS-CoV-2: From genomics to therapeutics
por: Shamsi, Anas, et al.
Publicado: (2021)

Pharmacological therapies and drug development targeting SARS-CoV-2 infection
por: Jiang, Yizhou, et al.
Publicado: (2022)

Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism
por: Strobelt, Romano, et al.
Publicado: (2022)

Targeting Spike Glycans to Inhibit SARS-CoV2 Viral Entry
por: Guseman, Alex J., et al.
Publicado: (2022)

XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection
por: Gerber, Pehuén Pereyra, et al.
Publicado: (2022)

Targeting spike glycans to inhibit SARS-CoV2 viral entry
por: Guseman, Alex J., et al.
Publicado: (2023)

Peptide Targets to SARS-CoV-2
por: Mandal, Santi M.
Publicado: (2020)

T Lymphocytes as Targets for SARS-CoV-2
por: Kuklina, Elena M.
Publicado: (2022)

Milk Peptides as Novel Multi‐Targeted Therapeutic Candidates for SARS-CoV2
por: Pradeep, H., et al.
Publicado: (2021)

In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV
por: Udofia, Inemesit A., et al.
Publicado: (2021)

The role of rilpivirine in Southern Africa
por: Moorhouse, Michelle A., et al.
Publicado: (2019)

Evaluation of the andrographolides role and its indoleamine 2,3-dioxygenase inhibitory potential and attendant molecular mechanism against STZ-induced diabetic rats
por: Kumar, Munipally Praveen, et al.
Publicado: (2020)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling
por: Grañana-Castillo, Sandra, et al.
Publicado: (2022)

State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2
por: Borgio, J. Francis, et al.
Publicado: (2020)

In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs
por: Chan, Wallace K. B., et al.
Publicado: (2022)

Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients
por: Wang, Luhong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n913btlrcpsc2s3l868e71drrr